Company
HongKong Rising Biotech features a streamlined organisational framework dedicated to biotechnology and micro-ecological therapeutics. Led by an expert team specialising in artificial intelligence, synthetic biology, and clinical dermatology, the company is structured around dedicated R&D pipelines, strategic academic partnerships, and core operational divisions focused on clinical treatments for skin diseases and functional skincare (DermaBalan®).
Description
HongKong Rising Biotech is an innovative biotechnology enterprise dedicated to AI-driven drug discovery and micro-ecological therapeutics. Leveraging a proprietary AI prediction and biosynthesis platform, the company integrates deep learning protein folding, high-throughput screening, and a massive resource library comprising thousands of drug-resistant pathogens and tens of thousands of genomic data sets. The company's core technological breakthroughs and pipelines include Staphyrase®, a next-gen micro-ecological anti-inflammatory material that selectively lyses harmful bacteria like Staphylococcus aureus while preserving beneficial skin microflora, utilised in both clinical hydrogels for wound care and the DermaBalan® functional skincare line. Additionally, HongKong Rising Biotech develops Phylac™ phage-based acne treatments, LABage™ microbiome therapies, and various specialised oral probiotics and postbiotics targeting metabolic health, gut-skin axis regulation, and immune support. Through strategic partnerships with leading marine research centres, medical institutions, and veterinary groups, the company actively drives clinical trials and multi-industry applications to advance modern biotechnology.
